The increasing cost of new healthcare technologies is leading payers to become more concerned about the financial impact of inappropriate or ineffective treatment. Manufacturers facing potential delays in market access or reimbursement are looking to innovative approaches including risk-sharing, pay-for-performance or value-based programs to allay the concerns of payers and health technology assessment programs. Biocom has organized this session to answer such questions as: What are the definitions of risk-sharing and value-based pricing programs? When are these programs needed? What are some of the successful examples? How do stakeholders view different programs? Can risk-sharing and value-based agreements provide competitive advantage to new healthcare technologies? More information and online registration is here.